NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.

[1]  B. Monk,et al.  The role of immune checkpoint inhibition in the treatment of ovarian cancer , 2016, Gynecologic Oncology Research and Practice.

[2]  Scott D. Brown,et al.  Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines , 2016, PloS one.

[3]  B. Nelson,et al.  PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. , 2016, Gynecologic oncology.

[4]  Yi-long Wu,et al.  Potential biomarker for checkpoint blockade immunotherapy and treatment strategy , 2016, Tumor Biology.

[5]  K. Yamaguchi,et al.  Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Brandes,et al.  Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. , 2015, The Lancet. Oncology.

[7]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[8]  C. Batt,et al.  Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer , 2014, Cancer Immunology Research.

[9]  J. Nemunaitis,et al.  First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients , 2012, Journal of Translational Medicine.

[10]  C. Morrison,et al.  Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients , 2012, Proceedings of the National Academy of Sciences.

[11]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[12]  K. Odunsi,et al.  Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity , 2011, The Journal of Immunology.

[13]  Andrew J. G. Simpson,et al.  CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens , 2008, Nucleic Acids Res..

[14]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[15]  F. Hodi.  Cytotoxic T-Lymphocyte–Associated Antigen-4 , 2007, Clinical Cancer Research.

[16]  K. Odunsi,et al.  Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[17]  K. Odunsi,et al.  Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 , 2006, The Journal of Immunology.

[18]  Yao-Tseng Chen,et al.  NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. , 2003, Cancer research.

[19]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  F. Tanaka,et al.  Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas , 2001, British Journal of Cancer.

[21]  Yao-Tseng Chen,et al.  Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.

[22]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[23]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[25]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[26]  Yao-Tseng Chen,et al.  Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Yao-Tseng Chen,et al.  Autoantibodies against cancer antigens. , 2009, Methods in molecular biology.

[28]  R. Coleman.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2007 .

[29]  Ook.,et al.  CYCLOPHOSPHAMIDE AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN IN PATIENTS WITH STAGE III AND STAGE IV OVARIAN CANCER , 2000 .